Amgen Inc.

Amgen Research (munich) Gmbh

Irwin Chen

Tobias Raum

Mark Leo Michaels

Claudia Blümel

Elisabeth Nahrwold

Christoph Dahlhoff

Tara Arvedson

Julie Bailis

Sandra Ross

Ian Nevin Foltz

Leslie Phillip Miranda

Zhulun Wang

Mei-Mei Tsai

Xiaoshan Min

Fang-Tsao Hong

Pavel V Bondarenko

Darren L Bates

Essa Hu Harrington

Donghui Shi

Jochen Pendzialek

Johannes Brozy

Alice Bakker

Monica Florio

David J Lloyd

Amy N Duguay

Benjamin M Alba

Susie Miki Harris

Daniel Lu

Jason C Long

Ryan B Case

Peng Li

Ian Driver

Joachim Wahl

Todd Hager

Aiko Umeda

Shilpa Sambashivan

Dora Toledo Warshaviak

Su Chong

Ian Foltz

Methods of treating metabolic diseases and disorders using an antigen binding protein specific for the GIPR polypeptide are provided. In various embodiments the metabolic disease or disorder is type 2 diabetes, obesity, dyslipidemia, elevated glucose levels, elevated insulin levels and diabetic nephropathy. In certain embodiments the antigen binding protein is administered in combination with a GLP-1 receptor agonist.

Method of treating or ameliorating metabolic disorders using binding proteins for gastric inhibitory peptide receptor (GIPR) in combination with GLP-1 agonists

The present invention provides bispecific antibody constructs characterized by comprising a first domain binding to MUC17, a second domain binding to an extracellular epitope of the human and theCD3ε chain and optionally a third domain, which is a specific Fc modality. Moreover, the invention provides a polynucleotide, encoding the antibody construct, a vector comprising this polynucleotide, host cells, expressing the construct and a pharmaceutical composition comprising the same.

Bispecific antibody construct directed to MUC17 and CD3

The present invention relates to an antibody construct comprising a domain which binds to Claudin 18.2 (CLDN18.2) and another domain which binds to CD3. Moreover, the invention provides a polynucleotide encoding the antibody construct, a vector comprising said polynucleotide and a host cell transformed or transfected with said polynucleotide or vector. Furthermore, the invention provides a process for producing the antibody construct of the invention, a medical use of said antibody construct and a kit comprising said antibody construct.

Antibody constructs for CLDN18.2 and CD3

Novel peptides that bind to human PAC1 are provided. These peptides that are antagonists of PAC1 are useful in a number of PAC1 related disorders, including the treatment and/or prevention of headache disorders, including migraine, such as acute migraine.

Peptide PAC1 antagonists

The present invention relates to antigen binding proteins, such as monoclonal antibodies, that specifically bind to and activate human triggering receptor expressed on myeloid cells-2 (TREM2) and pharmaceutical compositions comprising such antigen binding proteins. The agonist antigen binding proteins (e.g. antibodies) of the invention are capable of activating TREM2/DAP12 signaling in myeloid cells in the absence of Fc-mediated cross-linking of the antigen binding proteins. Methods of treating or preventing conditions associated with TREM2 loss of function, such as Alzheimer's disease and multiple sclerosis, using the antigen binding proteins are also described.

Anti-human TREM2 antibodies and uses thereof

The present application is directed to avimers and peptides and various combinations thereof in addition to methods of making and using them.

Inhibitory polypeptides specific to WNT inhibitors

Growing community of inventors

Los Angeles, CA, United States of America

Irwin Chen